Ryvu Therapeutics

Technologia zaczyna mieć realną wartość dopiero wtedy, gdy wychodzi poza laboratorium. Dlatego skuteczny transfer wiedzy i współpraca nauki z biznesem są dziś jednym z kluczowych elementów budowania konkurencyjności gospodarki. 18 maja w Warszawie odbyła się konferencja „Klubu Innowacji – Akademia dla przemysłu”, podczas której rozmawiano o projektach o dużym potencjale rynkowym, narzędziach wspierających komercjalizację wynalazków oraz o tym, jak systemowo zwiększać skuteczność transferu technologii z uczelni do przemysłu. W panelu dyskusyjnym pt. „Pieniądze to nie wszystko – co systemowo wspiera transfer technologii?” udział wzięła Aleksandra Sabiniarz, PhD. , Research Operations Director w Ryvu Therapeutics, reprezentując perspektywę biznesu i praktyczne spojrzenie na proces komercjalizacji innowacji. Spotkanie zorganizowało Centrum Transferu Technologii i Wiedzy | Uniwersytet Warszawski, a debatę poprowadził Mariusz Karwowski z Magazynu Forum Akademickie. Wśród panelistów znaleźli się również: ✔️ prof. dr hab. Jacek Jemielity – dyrektor Centrum Nowych Technologii UW, CEO ExploRNA ✔️Konrad Zawadzki – wicedyrektor Centrum Nauk Biologiczno-Chemicznych UW ✔️Anna Wnuk – dyrektor zarządzająca PSIK ✔️Zbigniew Leś – Director of R&D and Partnerships in Technology Transfer w The Heart Dziękujemy za inspirującą rozmowę o tym, jak skuteczniej łączyć potencjał nauki, biznesu i inwestorów, aby innowacje mogły szybciej trafiać do praktyki. 🙌 #RyvuTx #TransferTechnologii

Phase II is where clinical-stage biotech can turn science into value. The potential is in the asset. The outcome is in the execution.   This week, Kamil Sitarz, PhD, MBA, Chief Operating Officer & Board Member at Ryvu Therapeutics, will share how to approach this challenge at the 22nd Clinical Trials Strategic Summit in Munich, and what can be learned by building it from the inside.   If you are attending, come say hello!   #RyvuTx #ClinicalTrials #Oncology #Biotech #CTSS2026 #PhaseII #ClinicalDevelopment

Już 20 maja w Krakowie zapraszamy wszystkich związanych z branżą life science, medycyną, farmacją oraz sympatyków nowoczesnych technologii w ochronie zdrowia na wyjątkowy wieczór w ramach festiwalu popularnonaukowego Pint of Science Polska 🔬 Jednym z gości wydarzenia będzie Robert Dobosz, MSc, MBA z Ryvu Therapeutics, który opowie o współczesnym rozwoju leków i wyzwaniach stojących przed nowoczesną farmacją. Porozmawiamy m.in. o: 🧪 projektowaniu bardziej precyzyjnych terapii, 📋 bezpieczeństwie badań klinicznych, 🧫 nowoczesnych modelach badawczych, 🧠 technologiach wspierających rozwój nowych leków. To świetna okazja, aby zajrzeć za kulisy branży farmaceutycznej i dowiedzieć się, jak naprawdę wygląda droga leku od pomysłu do pacjenta. 📅 20 maja 2026 (środa) 🕕 18:00–21:00 📍 Klub Re, ul. Świętego Krzyża 4, Kraków Na scenie również: 🔹 prof. dr hab. Marcin Kołaczkowski (UJ CM) 🔹 dr inż. Konrad Kwiecień (AGH) 🎟️ Rejestracja i bilety: https://lnkd.in/dhEUVhMX Do zobaczenia! #RyvuTx #LifeScience #Biotech #BadaniaKliniczne

Ryvu Therapeutics continues to advance the clinical development of romaciclib (RVU120) with new Phase II data to be presented at #EHA2026 in Stockholm.    The upcoming presentations highlight encouraging results across two ongoing Phase II programs in hematologic malignancies:    🔹RIVER-81 – romaciclib combined with venetoclax demonstrated anti-leukemic activity and durable responses in patients with relapsed/refractory AML after failure of VEN-based therapy, supporting further development at the selected expansion dose.  🔹POTAMI-61 – romaciclib showed a favorable safety profile and clinical activity in myelofibrosis, both as monotherapy and in combination with ruxolitinib, supporting continued clinical evaluation.    These data further reinforce the potential of romaciclib’s differentiated CDK8/CDK19 inhibition approach across difficult-to-treat hematologic cancers.    📍 EHA 2026 | Stockholm, Sweden    📅RIVER-81 poster session: June 12, 2026 | 18:45–19:45 CEST  📅POTAMI-61 poster session: June 13, 2026 | 18:45–19:45 CEST    Abstracts are available here: https://ehaweb.org/      Read more: https://lnkd.in/dXNNyXcr ***  The project entitled “ The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent. ”, carried out by Ryvu Therapeutics S.A., is co-financed by the Polish Medical Research Agency (@Agencja Badań Medcznych) from the state budget under the “Development of targeted or personalised medicine based on medicinal products involving nucleic acids and small-molecule compounds” call (ABM/2022/6).   Total Project value: PLN 132,471,740.70;   Total funding: PLN 62,268,848.90

European biotech has the science and the clinical capability to run complex trials at scale. The question in 2026 is whether the ecosystem - capital, regulatory frameworks, exit pathways, and the people within it is catching up fast enough.   Kamil Sitarz, PhD, MBA, our COO, will be sharing his perspective on exactly that at OCT Europe 2026 in Barcelona across two panels.   📆 May 6, 2:00 PM CET 🎙️ The Biotech Landscape in Europe 2026: Growth, Shifts & Strategic Outlook ✔️ Where capital is actually flowing — and what investors want to see in 2026 ✔️ Talent gaps and how European biotechs compete for the right people ✔️ Regional shifts: why CEE clinical execution capability is an underused argument in investor conversations ✔️ How political and economic changes are reshaping strategic decisions across the continent   📆 May 7, 2:45 PM CET 🎙️ Future of Clinical Trial Professionals: Technology & Workforce Transformation ✔️ How AI and automation are reshaping roles across clinical trial functions ✔️ Ensuring human expertise drives technology — not the other way around   As COO of Ryvu Therapeutics, Kamil oversees several oncology programs running across Europe. These aren’t abstract questions.   If you’re attending OCT Europe, Kamil is happy to talk. 🙌   #OCTEurope2026 #ClinicalTrials #ClinicalOperations #Biotech #EuropeanBiotech #RyvuTx

Central and Eastern Europe is stepping into the spotlight as a catalyst for faster, smarter drug development, and we’re excited to be part of that conversation. Kamil Sitarz, PhD, MBA, COO at Ryvu Therapeutics, will be speaking at #BioEquityEurope 2026 in Prague on May 5. As part of the panel "Opportunities to Move Faster: Central and Eastern Europe", Kamil will share his perspective on biotech strategy, clinical development, and how the region can serve as a strategic execution hub for clinical-stage biotechs looking to accelerate timelines, reach global regulatory milestones faster, and ultimately create more value for biotechs, investors, and patients. He’ll be joined by leading experts from across the region: ✔️ David Feltl, Director at the National Oncology Center, Czech Republic ✔️ Irma U., Head of Clinical Operations at Biomapas   The discussion will be moderated by Steve Usdin, Washington Editor & Head of Policy & Regulation at BioCentury Inc., bringing a global policy and industry perspective to the conversation.   🕛 May 5 | 12:00–12:45 (CET) 📍 Prague   Join us to explore how this dynamic region is shaping the future of clinical trials and connect with Kamil during the event.   #RyvuTx #BioEquityEurope #Biotech #ClinicalTrials #DrugDevelopment #CEE #Oncology

Vatnak Vat-Ho will be representing Ryvu Therapeutics at #BioEquityEurope 2026! Looking forward to connecting with partners, investors, and innovators to explore opportunities in: 🔬 Novel small molecule drug discovery 🎯 Targeted oncology therapies 🧬 Early-stage pipeline development and partnering 🤝 Strategic collaborations in precision medicine If you're attending and interested in advancing cutting-edge therapies together, let’s connect with Vatnak on-site or via LinkedIn!

Krzysztof Brzozka and Mateusz Nowak are getting ready for the Antibody & ADC Summit in Shanghai. At Ryvu Therapeutics, ADCs aren’t just a topic we follow. They’re part of what we build. From smarter targeting to more effective payload delivery, we’re continually exploring how to advance this modality. This event is the perfect place to exchange ideas, challenge assumptions, and explore what’s next for antibody-drug conjugates alongside the global biotech community. If you’re attending and want to talk ADCs, let’s connect! #RyvuTx #ADC #antibody

The energy at AACR Annual Meeting 2026 is in full swing, and we’re proud to be part of it. 🙌 At this year’s meeting in San Diego, Ryvu Therapeutics is presenting new preclinical data on our ONCO Prime platform. ONCO Prime is an integrated precision oncology discovery platform that combines patient-derived models, engineered systems, and high-throughput CRISPR and omics analytics. It enables the identification of novel synthetic lethal vulnerabilities in genetically stratified colorectal cancer - including proof-of-concept validation with a clinically approved drug. Download the poster ⬇️ https://lnkd.in/d2GTfGf4 #RyvuTx #OncoPrime #AACR

"Clinical trials don’t fail due to lack of effort - they fail due to misalignment, outdated processes, and slow execution." That’s exactly what the 21st Clinical Trials Strategic Summit (CTSS) 2026 aims to address. Kamil Sitarz, our COO, will represent Ryvu Therapeutics on Panel 2: Optimizing Vendor–CRO Collaboration for Operational Success, joining industry leaders to share perspectives on how to improve collaboration and drive better trial outcomes. Kamil will be joined by: ✔️ B. Maria Thurman – Director, Clinical Portfolio Services, Vendor Management, Alnylam Pharmaceuticals (moderator) ✔️Jennifer Teti – VP, Head of Clinical Operations, Third Arc Bio ✔️Lisa M. – Director, Program Management, NextPoint Therapeutics, Inc. ✔️Paria Mahboub Johnson – Director Clinical Scientist, Kura Oncology, Inc. ✔️Audrey Rossow – Senior Director, Clinical Operations, Alzheon, Inc. Inc ✔️Kalyan Obalampalli (KO) – CEO, ClinAI 📍 Embassy Suites by Hilton Boston at Logan Airport 📅 April 22–23, 2026 If you’re focused on making clinical operations more effective, this is a conversation worth joining - don’t miss the opportunity to hear Ryvu’s perspective. Find out more: https://lnkd.in/gTRMA8tT #RyvuYx #CTSS2026 #ClinicalTrials #ClinicalOperations #CRO #ClinicalResearch